Imagine living with a condition that not only weakens your muscles but also wreaks havoc on your digestive system, making even the simplest acts of eating and digestion a daily struggle. This is the harsh reality for thousands of people with myotonic dystrophy type 1 (DM1), the most common form of adult-onset muscular dystrophy, affecting roughly 1 in 8,000 individuals. While muscle weakness and stiffness are well-known symptoms, DM1’s impact on the gastrointestinal (GI) tract is often overlooked—yet it’s a silent culprit behind a host of debilitating issues like difficulty swallowing, constipation, and even intestinal obstruction. But here’s where it gets controversial: despite 80% of DM1 patients suffering from these GI problems, the root causes have remained largely unexplored—until now.
Researchers at Baylor College of Medicine and collaborating institutions have developed the first mouse model that mirrors the GI challenges seen in DM1 patients. Their groundbreaking study, published in the Proceedings of the National Academy of Sciences, not only sheds light on the underlying mechanisms but also opens the door to potential treatments that could transform lives. And this is the part most people miss: the key to these GI issues might lie in something as seemingly simple as over-contracted gut muscles.
At the heart of DM1 is a mutation in the DMPK gene, where a repeating triplet of DNA building blocks (CTG) expands far beyond the normal range. While healthy individuals carry 5 to 37 CTG repeats, those with DM1 have 50 to over 3,000. This mutation produces faulty RNA molecules that trap essential proteins called muscleblind-like (MBNL). Normally, MBNL proteins help process RNA, including splicing genes, but when trapped, they can’t perform their vital functions. While this process is known to cause muscle stiffness, its role in GI problems has been a mystery—until this study.
To unravel this, the researchers selectively removed MBNL proteins from the smooth muscle cells lining the gut in mice. These cells are crucial for moving food through the digestive tract. What they found was eye-opening: food moved significantly slower through both the small intestine and colon in mice lacking MBNL proteins. Here’s the surprising twist: despite the gut tissue appearing normal under a microscope—no inflammation or nerve damage—the smooth muscle layers were thicker, and the small intestine was shorter. These changes pointed to one thing: the muscles were in a constant state of contraction.
Further experiments confirmed this over-contraction. When tested outside the body, gut segments from the DM1 model mice showed muscles that were more tense, contracted strongly at baseline, and remained tight after stimulation. This study provides the first clear evidence that the loss of MBNL proteins in smooth muscle alone can disrupt GI movements, a hallmark of DM1.
But here’s the controversial part: current treatments for DM1-related GI symptoms often involve drugs that stimulate gut movement, yet they frequently fail or produce mixed results. The researchers suggest a radical shift in approach: drugs that reduce gut muscle contraction might be far more effective. This idea is supported by recent case reports where antispasmodic drugs have relieved severe symptoms. Could we be treating these patients the wrong way all along?
Digging deeper, the team explored the molecular mechanisms behind these observations. They focused on the protein myosin light chain (MLC20), which plays a critical role in muscle contraction. When a phosphate tag is added to MLC20, muscles contract. In the DM1 gut model, they found higher levels of this phosphorylated MLC20, confirming the muscles were constantly contracted. Moreover, many other genes involved in muscle contraction were also affected, and strikingly, these changes were consistent between mice and humans, validating the model’s relevance.
Dr. Thomas A. Cooper, the study’s corresponding author, emphasizes, ‘DM1 is a complex disease, and GI symptoms have long been understudied. By creating a GI-specific mouse model and comparing it to human tissue, this study not only uncovered a key mechanism but also points to new therapeutic directions that could make a real difference for patients.’
Now, here’s where we want to hear from you: Do you think this shift in treatment approach—from stimulating to reducing gut muscle contraction—could be a game-changer for DM1 patients? Or are there other factors we’re missing? Share your thoughts in the comments below!**
This work was supported by grants from the NIH, the National Cancer Institute, the Cancer Prevention and Research Institute of Texas (CPRIT), and the National Institute of Diabetes and Digestive and Kidney Diseases, among others. The collaborative effort included researchers from Baylor College of Medicine, Texas Children’s Hospital, Oregon Health & Science University, and Stanford University, highlighting the importance of interdisciplinary research in tackling complex diseases like DM1.
